Update in the management of chronic lymphocytic leukemia

Table 1 Selected Trials in Previously Untreated CLL Patients

Reference	Regimen	Phase	No. Pts.	CR, %	ORR, %	Median PFS (months)
Eichhorst, 2006	Flu	III	164	7	83	20
	Flu + Cy		164	24	94	48
Flinn, 2007	Flu	III	137	5	59	19
	Flu + Cy		141	23	74	32
Catovsky, 2007	Chl	III	387	7	72	Not Rep
	Flu		194	15	80	Not Rep
	Flu + Cy		196	38	94	Not Rep
Byrd, 2003	FR (C)	Rand. II	51	47	90	NR
	FR (S)		53	28	77	NR
Keating, 2005	FCR	II	300	72	94	NR
Hallek, 2008	FC	III	409	23	85	32
	FCR		408	45	93	43
Kay, 2007	PCR	II	64	41	91	31
Kay, 2008	PR	II	33	30	79	12
Reynolds, 2008	PCR	III	92	7	45	Not Rep
	FCR		92	17	58	Not Rep

Key: No-Number; Flu-fludarabine; CLB-Chlorambucil; Cy-cyclophosphamide; Ritux-rituximab; FR (C) – fludarabine + rituximab, concurrent; FR (S) – fludarabine + rituximab, sequential; FCR – fludarabine, cyclophosphamide, rituximab; PCR – pentostatin, cyclophosphamide, rituximab; PR – pentostatin + rituximab; CR – complete response rate; ORR – overall response rate; PFS – progression free survival; NR – not reached; Not Rep – Not reported

ISSN: 1756-8722